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For some time, many people have been particularly con- 
cerned about the problems confronting clinical research in 
the United States. I was initially reluctant to discuss these 
problems because I am a clinical investigator and uncertain 
as to whether my perspective would be completely objec- 
tive. However, several recent developments have high- 
lighted the reality of these problems. One is the increasing 
proportion of clinical research performed outside the United 
States. For example, 39% of the abstracts submitted and 
42% of those selected for presentation for this year’s Annual 
Scientific Session originated abroad. In addition, surveys 
during our recent strategic planning process identified 
greater College support for clinical investigation as a high 
priority objective. I therefore believe that the perception that 
clinical research in the United States is facing serious 
dihiculties that could threaten its worldwide leadership role 
is correct. 
The fundamental requirements for all research are the 
availability of talented individuals and sound investigative 
protocols. In addition, the performance of clinical research 
requires time, equipment and patients. The current group of 
medical students, trainees and faculty clearly provides an 
abundant pool of capable and inquisitive individuals suitable 
for clinical investigation. However, significant problems are 
being encountered in obtaining the money and the patient 
populations necessary for such research. 
Although no one debates the necessity of both time and 
equipment to perform excellent research, it is often assumed 
when discussing clinical investigation that these resources 
are readily available as part of the process of providing 
patient care. Despite the commonality shared by many forms 
of clinical research and patient care, access to equipment 
and technician time often cannot be borrowed from patient 
care resources, and protected investigator time is required 
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for the planning, collection and analysis of research data. 
Accordingly, clinical research il! the United States will be 
jeopardized until we reject the notion that the requisite 
resources for such research can be drawn from those pro- 
vided for patient care and instead appropriate adequate 
money to fund these necessities. 
Decreased support for clinical research from the NIH and 
other government and private agencies. Funding for clinical 
research in prior years was in large measure provided by the 
National Institutes of Health (NIH). However, the progres- 
sive reduction in the funding of clinical investigation by the 
NIH is evidenced by the increasing number of PhD investi- 
gators applying for and receiving NIH support and serving 
on NIH study sections, as well as by stated NIH emphasis 
on basic science and molecular biology. Discouraged by a 
failure rate of approximately 65%, MD investigators progres- 
sively decreased their applications so that between 1975 and 
1987 the number of NIH grants awarded to MDs decreased 
from 27 to 22% of the total and MD investigators accounted 
for only 26% of awardees. Ancillary funding sources such as 
the American Heart Association (AHA) and the Veterans 
Administration have also increasingly directed support 
toward basic rather than clinical research. Thus, in 1988, 
MD researchers accounted for 25% of applicants for the 
AHA Established Investigator Award, but only 20% of 
awardees. With regard to AHA grants-in-aid, MD investiga- 
tors accounted for 35% of applicants, but only 25% of those 
who were awarded money. A recent cardiology Merit Re- 
view Board of the Veterans Administration, which has no 
basic science divisions, comprised two PhDs, two MD-PhDs 
and two additional members with appointments in basic 
science departments of other institutions. From 1983 to 1986 
the average rate of approval and funding for all Veterans 
Administration research proposals was 55%, but the rate for 
cardiology proposals was only 41%. Even in the College, 
programs such as the ACC/Merck Adult Cardiology Fellow- 
ship Training Awards, which were initially targeted toward 
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the support of clinical investigation, have increasingly been 
awarded to trainees doing basic laboratory investigation. 
Whereas it is a time-honored tenet that major advances in 
medicine usually follow understanding of basic mechanisms, 
the application of laboratory insights to patient care is also 
an important step. Furthermore, diagnostic and therapeutic 
advances-echocardiography and coronary angioplasty, for 
example--often are initiated in the clinical arena and subse- 
quently refined by studies in biology and physics; patient- 
based investigations, such as studies of angiography and 
surgery in acute myocardial infarction, often point the way 
to defining basic disease mechanisms such as thrombosis. 
Not surprisingly, many individuals have voiced concern that 
a significant imbalance is occurring between support for 
basic and clinical research. 
Growing relibnce on funds received from industry and 
patient care. Given the increasing difficulties in obtaining 
financial support for clinical research from the NIH and 
other granting agencies, clinical investigators have progres- 
sively turned to funds provided by medical industry and 
clinical income derived from patient care. Certainly the 
development, validation and definition of applications of 
new pharmaceutical agents and medical technology are 
prime areas for clinical investigation, and industry has been 
generous in supporting such endeavors. However, support 
from pharmaceutical and medical equipment sources is often 
limited to projects targeted toward the needs of the com- 
pany. Furthermore, industry support creates the potential 
for bias in the generation and interpretation of scientific data. 
The increasing reliance on industry for funding represents an 
additional significant peril to clinical research. 
A second major source of monies utilized for clinical 
research in recent years is income generated from patient 
care. However, the generation of research funding from 
clinical income has its own set of difficulties. The time 
required to cultivate a patient flow and render clinical 
services so that clinical income can be generated detracts 
from time available to perform good clinical research. Al- 
though it has been argued that faculty members dedicated to 
patient care and without an interest in investigation may 
alleviate this difficulty, physicians often see this role as 
second class citizenship, and the wide differences in financial 
compensation between private practice and academic med- 
icine make it difficult to attract-and retain-outstanding 
individuals to academic practice. The generation of clinical 
income in academic institutions is further complicated by the 
fact that such centers often provide medical care for a large 
segment of the indigent population, a segment in which low 
collection rates mandate a greater work load for a given 
profit. The ability to use patient care income for clinical 
research is particularly compromised in cardiology because 
the profits generated by the delivery of services are custom- 
arily utilized to support the department of medicine. Accord- 
ingly, in an attempt to generate patient care income to 
support clinical research, cardiovascular faculty often ex- 
pend enormous time and effort in the practice of medicine to 
yield sums of money that are largely utilized to support other 
activities within the institution. The generation of clinical 
income is, of course, dependent on an adequate flow of 
patients, a topic requiring the in-depth discussion to follow. 
Competition for patients between academic centers and 
community hospitals. Assuming the existence of adequate 
time and equipment, the final requirement for clinical re- 
search is patient population. Outside of the United States the 
regionalization of health care often directs suitable numbers 
of patients to academic centers where clinical investigation 
is performed. Undoubtedly, this has played a role in the 
increased quantity of clinical research being performed 
abroad. However, in the United States, academic centers 
must compete with community hospitals for patients and are 
at a marked disadvantage in this competition. Academic 
institutions tend to be large and imposing and are often 
primarily responsible for the indigent care in their area, all of 
which may create a negative image in the eyes of private 
patients. The personal interests of physicians in teaching and 
research that lead them to join medical school faculty also 
often result in their tendency to show little interest in the 
amenities of practice and the marketing of services. The 
presence of medical students and trainees as part of the team 
of physicians caring for patients contributes to the imper- 
sonal air of the institution, as well as the sense that the 
patient may well be the subject of experimentation. Given 
these circumstances, it is not surprising that a substantial 
proportion of patients, particularly those with favorable 
insurance coverage, gravitate toward community hospitals. 
Accordingly, a mismatch often evolves in which community 
hospitals with little interest in investigation have the requi- 
site quantity and type of patient material for clinical re- 
search, whereas academic institutions with the expertise and 
enthusiasm necessary for high quality clinical research suffer 
from a lack of optimal patient flow. This disjunction between 
clinical material and investigative expertise has profound 
implications for studying disease processes, evaluating new 
diagnostic modalities and assessing pharmaceutical and non- 
pharmaceutical therapeutic interventions. 
Need for practitioners to participate in clinical research. 
One obvious potential remedy to solve any imbalance be- 
tween clinical material and investigative expertise that may 
exist in community and academic hospitals would be active 
participation of private practitioners in clinical research. 
However, these physicians have recently shown an alarming 
trend toward withdrawal from clinical research that may be 
driven by traditional town-gown wariness, a growing atmo- 
sphere of competition, nonrecognition of significant unre- 
solved medical issues, an inability to visualize an important 
role for themselves in research efforts or difficulties in 
undertaking the extra work, possible financial expenses and 
often onerous bookkeeping of the protocol. In a recent 
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article in the Washington Post, the National Cancer Institute 
decried the lack of recruitment of cancer patients into 
investigative therapeutic protocols. Lawrence Friedman, 
MD, Acting Associate Director of the Clinical Applications 
and Prevention Program of the National Heart, Lung, and 
Blood Institute, has also commented on the difficulties 
encountered in enrolling patients from the private sector in 
several multicenter cardiovascular protocols currently un- 
derway. Although nonacademicians in community hospitals 
have played a significant role in several areas of clinical 
research, their efforts have often been limited to assessment 
of new technologies that served the additional purpose of 
enhancing the image of the physicians and their institutions 
in the eyes of the public. If the United States is to maintain 
its leadership position in clinical research, the interest and 
enthusiasm for inquiry must be rekindled in private practi- 
tioners, and the machinery must be put in place to facilitate 
their participation in investigative efforts. 
Required actions. Given the many factors that threaten 
the future of clinical research in the United States, I believe 
a number of corrective actions are both readily apparent and 
essential. First, clinical research requires the unencumbered 
time of physician investigators, and granting agencies must 
recognize the necessity of financial support for this purpose. 
Specifically, I believe the NIH and other granting agencies 
must assess whether an inappropriate imbalance is occurring 
between the support available for basic laboratory studies 
and clinical research. Given the large number of basic 
scientists serving on existing study sections, some cardio- 
vascular leaders have suggested the implementation of sep- 
arate review panels staffed by clinical investigators to eval- 
uate clinical research proposals. Second, to whatever degree 
that support for clinical research must be derived from funds 
for patient care, the generation of such funds should be 
facilitated and made as efficient as possible. Academic 
medical centers must become as attractive as possible as 
centers for patient care. Academic institutions, and depart- 
ments of medicine in particular, must find alternate sources 
to subsidize activities incapable of generating independent 
support. Highly motivated clinical investigators willing to 
forego personal salary and deliver extensive patient care to 
fund clinical research will soon abandon their effort if the 
dollars are diverted to other areas within the institution. 
Third, support for clinical research from medical industry, 
currently an important basis of much investigation, should 
be acknowledged and increased. More importantly, mecha- 
nisms should be devised whereby at least some industry 
dollars can be applied to investigation that is not directly 
targeted to the marketing of a product and that enable data 
generated by virtue of industry contributions to be processed 
so as to avoid any potential bias. Finally, it must be 
acknowledged that large scale clinical trials addressing crit- 
ical medical dilemmas will require the active and enthusias- 
tic participation of the private practicing cardiovascular 
specialist. Steps must be taken to remove all unreasonable 
work and financial burdens from research protocols and to 
convince practicing physicians that they have an important 
role-and an obligation to participate-in the discovery of 
new medical knowledge. The failure of practitioners to join 
investigative efforts will not only imperil clinical research in 
the United States, but also result in the delay and possible 
failure to make important advances in the clinical care 
delivered to our patients. 
